Colorectal cancer
Conditions
Interventions
A group(three taimes-daily) UFT was administered at a dose of 300 mg/m2/day, and LV was administered at a dose of 75 mg/day. The daily doses of both UFT and LV were divided into three doses administe
Sponsors
Multicenter Study Group of Osaka (MCSGO), Colorectal Cancer Treatment Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Histologically proven, Stage II, III, (Japanese Classification of Colorectal cancer 7th Ehition) primary Colorectal adenocarcinoma (eliminating appendiceal cancer). 2)Curability A 3)Age between 20 and 80 years. 4)Performance status(ECOG) of 0-1. 5)No prior therapy expect the operation. 6)Capability of oral intake 7)Patients who have satisfied the following the clinical test values within two weeks before the registration. 1.Neutrophile:>= 1,500/mm3 2.Platelet:>= 100,000/mm3 3.Hemoglobin:>= 9.0g/dL 4.Total bilirubin: < 2.0 mg/dL 5.AST, ALT: <100IU/L 6.Serum creatinine: <1.5mg/dL 8)Patient with starting the treatment within 8 weeks after operation. 9)Written informed consent.
Exclusion criteria
Exclusion criteria: 1)Active synchronous or metachronous malignancy carcinoma in situ. 2)Severe postoperative complications. 3)Severe complication. 4)Severe diarrhea. 5)Severe infectious disease. 6)Medical history of severe anaphylaxis or allergia to any drug. 7)Undergoing treatment with fluorocytosine. 8)Pregnant or lactating woman at any time during study. Men of the fertility hope. 9)Severe mental disorder. 10)Patients judged inappropriate for the study by their physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year Disease-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival Adverse events, Completion rate of treatment Compliance | — |
Countries
Japan
Contacts
Public ContactMamoru Uemura
Osaka University Graduate School of Medicine Department of Surgery
Outcome results
None listed